Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646409 | 0.91 | MEN1 (0.47) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL4687933 | 0.91 | MEN1 (0.47) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL14025310 | 0.87 | MEN1 (0.43) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL4646869 | 0.82 | NEK1 (0.47) | MEN1KMT2ANEK1POLBMMP2 | |
| SCHEMBL14025315 | 0.80 | NEK1 (0.55) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL4647511 | 0.80 | NEK1 (0.52) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL4648410 | 0.79 | NEK1 (0.56) | MEN1KMT2AMMP7NEK1POLB | |
| SCHEMBL4648789 | 0.72 | NR3C1 (0.49) | MEN1KMT2ANEK1POLBMMP2 | |
| SCHEMBL4685322 | 0.72 | NR3C1 (0.47) | MEN1KMT2ANEK1POLBMMP2 | |
| SCHEMBL4647690 | 0.72 | NR3C1 (0.47) | MEN1KMT2ANEK1POLBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | claimed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | claimed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | claimed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | FSHR, NPY1R, GNRHR | MEN1 302/4885KMT2A 1685/4885MMP7 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.